| Modeling the cost‐effectiveness of doula care associated with reductions in preterm birth and cesarean delivery KB Kozhimannil, RR Hardeman, F Alarid‐Escudero, CA Vogelsang, ... Birth 43 (1), 20-27, 2016 | 197 | 2016 |
| Microsimulation modeling for health decision sciences using R: a tutorial EM Krijkamp, F Alarid-Escudero, EA Enns, HJ Jalal, MGM Hunink, ... Medical Decision Making 38 (3), 400-422, 2018 | 138 | 2018 |
| The household secondary attack rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a rapid review HF Fung, L Martinez, F Alarid-Escudero, JA Salomon, DM Studdert, ... Clinical Infectious Diseases 73 (Supplement_2), S138-S145, 2021 | 118 | 2021 |
| An overview of R in health decision sciences H Jalal, P Pechlivanoglou, E Krijkamp, F Alarid-Escudero, E Enns, ... Medical decision making 37 (7), 735-746, 2017 | 104 | 2017 |
| A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer NJ Sathianathen, F Alarid-Escudero, KM Kuntz, N Lawrentschuk, ... European urology oncology 2 (6), 649-655, 2019 | 57 | 2019 |
| A Gaussian approximation approach for value of information analysis H Jalal, F Alarid-Escudero Medical Decision Making 38 (2), 174-188, 2018 | 56 | 2018 |
| Comparing the cost-effectiveness of innovative colorectal cancer screening tests EFP Peterse, RGS Meester, L de Jonge, AH Omidvari, F Alarid-Escudero, ... JNCI: Journal of the National Cancer Institute 113 (2), 154-161, 2021 | 52 | 2021 |
| Covid-19 in the California state prison system: an observational study of decarceration, ongoing risks, and risk factors ET Chin, T Ryckman, L Prince, D Leidner, F Alarid-Escudero, JR Andrews, ... Journal of General Internal Medicine 36 (10), 3096-3102, 2021 | 50 | 2021 |
| Estimated quality of life and economic outcomes associated with 12 cervical cancer screening strategies: a cost-effectiveness analysis GF Sawaya, E Sanstead, F Alarid-Escudero, K Smith-McCune, ... JAMA internal medicine 179 (7), 867-878, 2019 | 48 | 2019 |
| Outbreaks of COVID-19 variants in US prisons: a mathematical modelling analysis of vaccination and reopening policies T Ryckman, ET Chin, L Prince, D Leidner, E Long, DM Studdert, ... The Lancet Public Health 6 (10), e760-e770, 2021 | 46 | 2021 |
| Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis EA Burger, IMCM De Kok, E Groene, J Killen, K Canfell, S Kulasingam, ... JNCI: Journal of the National Cancer Institute 112 (9), 955-963, 2020 | 46 | 2020 |
| A need for change! A coding framework for improving transparency in decision modeling F Alarid-Escudero, EM Krijkamp, P Pechlivanoglou, H Jalal, SYZ Kao, ... Pharmacoeconomics 37 (11), 1329-1339, 2019 | 46 | 2019 |
| Midwife‐led care and obstetrician‐led care for low‐risk pregnancies: a cost comparison LB Attanasio, F Alarid‐Escudero, KB Kozhimannil Birth 47 (1), 57-66, 2020 | 45 | 2020 |
| Cost-effectiveness analysis of active surveillance strategies for men with low-risk prostate cancer NJ Sathianathen, BR Konety, F Alarid-Escudero, N Lawrentschuk, ... European urology 75 (6), 910-917, 2019 | 44 | 2019 |
| Incorporating biomarkers into the primary prostate biopsy setting: a cost-effectiveness analysis NJ Sathianathen, KM Kuntz, F Alarid-Escudero, NL Lawrentschuk, ... The Journal of urology 200 (6), 1215-1220, 2018 | 44 | 2018 |
| Covid-19 vaccine acceptance in california state prisons ET Chin, D Leidner, T Ryckman, YE Liu, L Prince, F Alarid-Escudero, ... New England Journal of Medicine 385 (4), 374-376, 2021 | 42 | 2021 |
| Calculating the expected value of sample information in practice: considerations from 3 case studies A Heath, N Kunst, C Jackson, M Strong, F Alarid-Escudero, ... Medical Decision Making 40 (3), 314-326, 2020 | 41 | 2020 |
| Computing the expected value of sample information efficiently: practical guidance and recommendations for four model-based methods N Kunst, ECF Wilson, D Glynn, F Alarid-Escudero, G Baio, A Brennan, ... Value in Health 23 (6), 734-742, 2020 | 34 | 2020 |
| “Time traveling is just too dangerous” but some methods are worth revisiting: the advantages of expected loss curves over cost-effectiveness acceptability curves and frontier F Alarid-Escudero, EA Enns, KM Kuntz, TL Michaud, H Jalal Value in Health 22 (5), 611-618, 2019 | 32 | 2019 |
| A summary of the 2020 gastric cancer summit at Stanford University RJ Huang, H Koh, JH Hwang, CC Abnet, F Alarid-Escudero, MR Amieva, ... Gastroenterology 159 (4), 1221-1226, 2020 | 29 | 2020 |
Hawre JalalAssociate Professor, University of OttawaVerified email at uottawa.ca
